Patents by Inventor Li Xing

Li Xing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240174648
    Abstract: Provided is a small molecule compound, which is characterized in having the structure represented by the following molecular formula: (I), wherein X1 and X2 are selected from carbon or nitrogen; G1 is a carbocyclic ring or heterocyclic ring having aromaticity; any one or more hydrogen atoms on the ring of G1 are substituted by R1; and R1 is selected from nitrogen-containing groups. The small molecule compound of the present invention can be used as a highly effective and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor; and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 or Tyk2/JAK1, Tyk2/Jak2 dual inhibitor.
    Type: Application
    Filed: October 10, 2020
    Publication date: May 30, 2024
    Inventors: Li Xing, Guanqun Li, Xiaolei Wang, Yuting Cai, Xiang Jiang, Xiang Pan, Wenhao Zhu, Yang Wang, Zengquan Wang
  • Patent number: 11834432
    Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: December 5, 2023
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Ao Zhang, Meiyu Geng, Li Xing, Jing Ai, Zilan Song, Xia Peng, Wangting Gu, Jian Ding
  • Publication number: 20230084672
    Abstract: A sanding tool includes a baseplate assembly, a housing assembly, a drive mechanism, and a fan assembly. The baseplate assembly includes a baseplate. The housing assembly includes a body housing. The housing assembly further includes a functional housing, where a hollow cavity is formed in the functional housing, the functional housing is provided with an inlet and an outlet that communicate with the hollow cavity, the inlet communicates with a dust removal channel of the sanding tool, the outlet is configured to discharge gas in the cavity, and the fan assembly is used for forming a dust removal air path moving towards the inlet. A ratio of an area of a projection of the functional housing on the baseplate to an area of the baseplate is greater than or equal to 0.15 and less than or equal to 0.95.
    Type: Application
    Filed: November 15, 2022
    Publication date: March 16, 2023
    Inventors: Zhongquan Xu, Lingjian Shi, Tianliang Liu, Mingtan Fu, Lisong Zhang, Li Xing
  • Publication number: 20220411408
    Abstract: Provided in the present invention is a small molecule compound, which is characterized in that it is a compound or a stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite, and pharmaceutically acceptable salt or prodrug of the compound as represented by the following structural formula: formula (I). The small molecule compound of the present invention is applicable as a highly efficient and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor.
    Type: Application
    Filed: October 10, 2020
    Publication date: December 29, 2022
    Inventors: Li Xing, Guanqun Li, Xiaolei Wang, Yuting Cai, Xiang Jiang, Xiang Pan, Wenhao Zhu, Yang Wang, Zengquan Wang
  • Publication number: 20220204518
    Abstract: The present invention relates to a pyrimido[5,4-b]pyrrolizin compound represented by general formula I, an optical isomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use thereof. The compound according to the present invention has good inhibitory activity on the kinase BTK at both the molecular level and the cellular level. Meanwhile, the compound also has good anti-tumor activity and pharmacokinetic properties in vivo.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Inventors: Ao ZHANG, Jian DING, Hua XIE, Zilan SONG, Yu XUE, Li XING, Linjiang TONG, Meiyu GENG
  • Publication number: 20220143774
    Abstract: A sanding tool includes a machine body, a power supply, a base plate assembly, a drive mechanism, and a control mechanism. The machine body includes a casing. The base plate assembly includes a base plate. The drive mechanism is disposed in the casing and includes a motor and an output shaft, the motor has a motor shaft rotating around a first axis, the output shaft rotates around a second axis, and the output shaft transmits power to the base plate assembly. The control mechanism is electrically connected to the motor and configured to control the sanding tool to operate. The first axis and the second axis form an included angle and are not in the same plane. A battery pack and the motor are disposed on two sides of the output shaft.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 12, 2022
    Inventors: Lisong Zhang, Li Xing
  • Patent number: 11197867
    Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: December 14, 2021
    Assignee: Pfizer Inc.
    Inventors: Andrew Fensome, Ariamala Gopalsamy, Brian S. Gerstenberger, Ivan Viktorovich Efremov, Zhao-Kui Wan, Betsy Pierce, Jean-Baptiste Telliez, John I. Trujillo, Liying Zhang, Li Xing, Eddine Saiah
  • Publication number: 20210377495
    Abstract: Methods of treatment as Janus Kinase inhibitors containing the compound of the invention having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N; A is selected from the group consisting of a bond and C?O; R1 is C3-C6 cycloalkyl, wherein said cycloalkyl is further optionally substituted with one or more halo; R2 is hydrogen; R3 is hydrogen; R4 is monocyclic heteroaryl wherein said heteroaryl is optionally substituted with one or more C1-C6 alkyl; and, R5 is hydrogen; and, j is 0 or 1.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 2, 2021
    Applicant: Pfizer Inc.
    Inventors: Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
  • Patent number: 10980815
    Abstract: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C?O, —SO2—, etc.; A? is selected from the group consisting of a bond, C?O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1? are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: April 20, 2021
    Assignee: Pfizer Inc.
    Inventors: Andrew Fensome, Ariamala Gopalsamy, Brian S. Gerstenberger, Ivan Viktorovich Efremov, Zhao-Kui Wan, Betsy Pierce, Jean-Baptiste Telliez, John I. Trujillo, Liying Zhang, Li Xing, Eddine Saiah
  • Publication number: 20210002251
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Applicant: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Publication number: 20200397817
    Abstract: A method for treating cancer includes the steps of: administering to a subject an effective amount of zero valent iron (ZVI) nanoparticles and an effective amount of at least one resistance modulating agent. The shell of each of the ZVI nanoparticles includes gold (Au). The resistance modulating agent includes inducers of programmed cell death, such as erastin, sulfasalazine, sorafenib, buthionine sulfoximine, Ras selective lethal 3 (RSL-3), altretamine, and FIN56. The resistance modulating agent can induce ferroptosis, promote lipid peroxidation, block NADP(H) supply, or suppress metabolism of polyunsaturated fatty acids. Alternatively, the resistance modulating agent can suppress expression of at least one of GSR, AKR1C1, AKR1C3, AKR1B1, AKR1B10 and KYNU genes or promote expression of at least one of ACSL4, ZEB1 and NNMT genes. A method for improving efficacy of a cancer treatment using the ZVI nanoparticles and another method for treating cancer are also provided.
    Type: Application
    Filed: November 30, 2017
    Publication date: December 24, 2020
    Inventors: DAR-BIN SHIEH, KUANG-JING HUANG, LI-XING YANG
  • Patent number: 10815213
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Publication number: 20200330477
    Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.
    Type: Application
    Filed: July 2, 2020
    Publication date: October 22, 2020
    Applicant: Pfizer Inc.
    Inventors: Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
  • Publication number: 20200172510
    Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 4, 2020
    Inventors: Ao ZHANG, Meiyu GENG, Li XING, Jing AI, Zilan SONG, Xia PENG, Wangting GU, Jian DING
  • Patent number: 10605260
    Abstract: Rotor of a gas turbine engines having a rotor hub and a plurality of blades extending from the rotor hub, wherein each blade has a full-span forward sweep along a leading edge of the blade that starts at an airfoil root of the blade at the hub and extends to a blade tip, wherein a sweep of a blade is a percentage of a root axial chord length of the respective blade.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 31, 2020
    Assignee: UNITED TECHNOLOGIES CORPORATION
    Inventors: Li Xing Pan, Yuan Dong, Simon W. Evans, Robert W. Fessenden, Sue-Li Kingsley Chuang, Sean Nolan
  • Publication number: 20200038409
    Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.
    Type: Application
    Filed: September 24, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
  • Publication number: 20200039960
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Publication number: 20190387710
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • Publication number: 20190390688
    Abstract: A compressor may include an airfoil configured to rotate about an axis. The airfoil may have a span measured radially from a root of the airfoil to a tip of the airfoil. A compressor case may be radially adjacent to the airfoil. The airfoil and the compressor case may define a clearance between the tip of the airfoil and a radially inner surface of the compressor case. A ratio of the clearance to the span may be 2.5 percent or less. A mass flow rate of the compressor may be 3.0 pounds-mass per second or less.
    Type: Application
    Filed: August 5, 2019
    Publication date: December 26, 2019
    Applicant: UNITED TECHNOLOGIES CORPORATION
    Inventors: Robert W. FESSENDEN, Abhir A. ADHATE, Yuan DONG, Sean NOLAN, Li Xing PAN
  • Patent number: 10493129
    Abstract: The present invention provides a novel use of fibroblast growth factor 2 (FGF-2), i.e., a use of FGF-2 in preparation of medicine. The uses of the medicine are the following (a) and/or (b) and/or (c): (a) the prevention and/or treatment of lung injury; (b) the prevention and/or treatment of influenza; (c) the prevention and/or treatment of diseases caused by influenza viruses.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 3, 2019
    Assignee: BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY
    Inventors: Xiliang Wang, Chengyu Jiang, Penghui Yang, Xin Liu, Yueqiang Duan, Li Xing, Chengcai Lai